These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 15151466

  • 1. Bosentan.
    Chin K, Channick R.
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
    Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV.
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension].
    MMW Fortschr Med; 2004 Dec 09; 146(50):72-3. PubMed ID: 15666438
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Response to bosentan in children with pulmonary hypertension.
    Maiya S, Hislop AA, Flynn Y, Haworth SG.
    Heart; 2006 May 09; 92(5):664-70. PubMed ID: 16216850
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N, Kilpatrick D.
    Future Cardiol; 2011 Jan 09; 7(1):19-37. PubMed ID: 21174507
    [Abstract] [Full Text] [Related]

  • 18. Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan.
    Safdar Z.
    Respir Med; 2009 Nov 09; 103(11):1688-92. PubMed ID: 19539456
    [Abstract] [Full Text] [Related]

  • 19. Bosentan for chronic thromboembolic pulmonary hypertension.
    Confalonieri M, Kodric M, Longo C, Vassallo FG.
    Expert Rev Cardiovasc Ther; 2009 Dec 09; 7(12):1503-12. PubMed ID: 19954311
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ.
    J Am Coll Cardiol; 2006 Oct 03; 48(7):1433-7. PubMed ID: 17010807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.